Alnylam Pharmaceuticals
ALNY
#625
Rank
A$50.18 B
Marketcap
$389.13
Share price
1.06%
Change (1 day)
39.97%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Alnylam Pharmaceuticals (ALNY) - Total debt

Total debt on the balance sheet as of September 2024 : A$2.05 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's total debt is A$2.05 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Alnylam Pharmaceuticals - Total debt on balance sheet (from 2003 to 2024)

Total debt by year

Year Total debt Change
2023-12-31A$1.91 B-1.24%
2022-12-31A$1.94 B40.99%
2021-12-31A$1.37 B103.01%
2020-12-31A$0.67 B56.2%
2019-12-31A$0.43 B919.01%
2018-12-31A$42.58 M10.82%
2017-12-31A$38.42 M-81.53%
2016-12-31A$0.20 B
2007-12-31A$7.72 M-33.3%
2006-12-31A$11.58 M14.67%
2005-12-31A$10.1 M8.61%
2004-12-31A$9.3 M272.07%
2003-12-31A$2.5 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
A$0.80 B-60.78%๐Ÿ‡บ๐Ÿ‡ธ USA
A$4.26 B 107.71%๐Ÿ‡บ๐Ÿ‡ธ USA
A$2.20 B 7.35%๐Ÿ‡บ๐Ÿ‡ธ USA
A$0.80 B-60.65%๐Ÿ‡บ๐Ÿ‡ธ USA
A$0.75 M-99.96%๐Ÿ‡บ๐Ÿ‡ธ USA
A$50.74 B 2,370.29%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
A$40.17 B 1,855.76%๐Ÿ‡ซ๐Ÿ‡ท France
A$30.41 B 1,380.61%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel